ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
This study has been completed.
Sponsor:
Transition Therapeutics Ireland Limited
Collaborator:
Transition Therapeutics
Information provided by (Responsible Party):
Transition Therapeutics Ireland Limited
ClinicalTrials.gov Identifier:
NCT00934050
First received: June 29, 2009
Last updated: May 12, 2015
Last verified: May 2015
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
| Condition | Intervention | Phase |
|---|---|---|
|
Alzheimer's Disease |
Drug: ELND005 (scyllo-inositol) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease |
Resource links provided by NLM:
Genetics Home Reference related topics:
Alzheimer disease
MedlinePlus related topics:
Alzheimer's Disease
Drug Information available for:
Inositol
U.S. FDA Resources
Further study details as provided by Transition Therapeutics Ireland Limited:
Primary Outcome Measures:
- Treatment Emergent Adverse Events (TEAEs) [ Time Frame: 12 months ] [ Designated as safety issue: No ]Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs)
| Enrollment: | 103 |
| Study Start Date: | June 2009 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: ELND005 |
Drug: ELND005 (scyllo-inositol)
Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks After 15Dec2009: ELND005 250 mg PO BID for 48 weeks Other Name: scyllo-inositol
|
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.
Exclusion Criteria:
- Subject has no new medical contraindications to continued participation in the study.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00934050
Hide Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00934050
Hide Study Locations
Locations
| United States, Arizona | |
| Banner Alzheimer's Institute | |
| Phoenix, Arizona, United States, 85006 | |
| Sun Health Research Institute | |
| Sun City, Arizona, United States, 85351 | |
| University of Arizona, Health Sciences Center, Dept. of Neurology | |
| Tucson, Arizona, United States, 85724 | |
| United States, California | |
| Margolin Brain Institute | |
| Fresno, California, United States, 93720 | |
| Collaborative NeuroScience Network, Inc. | |
| Garden Grove, California, United States, 92845 | |
| United States, Connecticut | |
| Yale University School of Medicine, Alzheimer's Disease Research Unit | |
| New Haven, Connecticut, United States, 06510 | |
| United States, Florida | |
| Brain Matters Research | |
| Delray Beach, Florida, United States, 33445 | |
| Sunrise Clinical Research, Inc | |
| Hollywood, Florida, United States, 33021 | |
| Roskamp Institute | |
| Sarasota, Florida, United States, 34243 | |
| Premiere Research Institute | |
| West Palm Beach, Florida, United States, 33407 | |
| United States, Georgia | |
| Emory University, Dept. of Neurology | |
| Atlanta, Georgia, United States, 30329 | |
| Dekalb Neurology Associates, LLC | |
| Decatur, Georgia, United States, 30033 | |
| United States, Indiana | |
| Department of Neurology - Indiana University Medical Center | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Kansas | |
| University of Kansas Medical Center, Department of Neurology | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Kentucky | |
| Innovative Clinical Concepts | |
| Paducah, Kentucky, United States, 42003 | |
| United States, New Jersey | |
| Memory Enhancement Center of America, Inc. | |
| Eatontown, New Jersey, United States, 07724 | |
| Global Medical Institutes | |
| Princeton, New Jersey, United States, 08540 | |
| United States, New Mexico | |
| Albuquerque Neuroscience, Inc. | |
| Albuquerque, New Mexico, United States, 87109 | |
| United States, New York | |
| Neurological Associates of Albany, PC | |
| Albany, New York, United States, 12208 | |
| Columbia University Sergievsky Center | |
| New York, New York, United States, 10032 | |
| AD-CARE, Monroe Community Hospital | |
| Rochester, New York, United States, 14620 | |
| United States, North Carolina | |
| Raleigh Neurology Associates | |
| Raleigh, North Carolina, United States, 27607 | |
| United States, Ohio | |
| Neurology & Neuroscience Center of Ohio | |
| Toledo, Ohio, United States, 43623 | |
| United States, Oregon | |
| Medford Neurological and Spine Clinic | |
| Medford, Oregon, United States, 97504 | |
| Summit Research Newtwork, Inc. | |
| Portland, Oregon, United States, 97210 | |
| United States, Pennsylvania | |
| The Clinical Trial Center, LLC | |
| Jenkintown, Pennsylvania, United States, 19046 | |
| University of Pittsburgh Alzheimer Disease Research Clinic | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Rhode Island | |
| Butler Hospital, Memory and Aging Center | |
| Providence, Rhode Island, United States, 02906 | |
| United States, South Carolina | |
| Alliance for Neuro Research, LLC dba Absher Neurology, PA | |
| Greenville, South Carolina, United States, 29615 | |
| United States, Vermont | |
| Clinical Neuroscience Research Associates, Inc-The Memory Clinic | |
| Bennington, Vermont, United States, 05201 | |
| Canada, Alberta | |
| Glenrose Rehabilitation Hospital | |
| Edmonton, Alberta, Canada, T5G 0B7 | |
| Canada, British Columbia | |
| University of British Columbia Hospital, Division of Neurology | |
| Vancouver, British Columbia, Canada, V6T 2B5 | |
| Canada, Ontario | |
| Parkwood Hospital | |
| London, Ontario, Canada, N6C 5J1 | |
| Sisters of Charity of Ottawa Health Service | |
| Ottawa, Ontario, Canada, K1N 5C8 | |
| Kawartha Regional Memory Clinic | |
| Peterborough, Ontario, Canada, K9H 2P4 | |
| Whitby Mental Health Memory Clinic | |
| Toronto, Ontario, Canada, M5T 2S8 | |
| Gerontion Research, Inc. | |
| Toronto, Ontario, Canada, M6M 3Z5 | |
| Canada, Quebec | |
| Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont) | |
| Montreal, Quebec, Canada, H1T 2M4 | |
Sponsors and Collaborators
Transition Therapeutics Ireland Limited
Transition Therapeutics
More Information
| Responsible Party: | Transition Therapeutics Ireland Limited |
| ClinicalTrials.gov Identifier: | NCT00934050 History of Changes |
| Other Study ID Numbers: | ELND005-AD251 |
| Study First Received: | June 29, 2009 |
| Results First Received: | April 22, 2015 |
| Last Updated: | May 12, 2015 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders |
Mental Disorders Inositol Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 27, 2016